RE:How come a basket...The broader biotech rally since the Trump win is applying to the larger mainstream biotech names rather than the backwaters of the CVE. While investing in companies listed on the CVE can insulate you from market downturns, it comes at the disadvantage of missing out on the rallies. Short term traders will also dump the small names in order to get capital to invest in the broader rally. Professional traders know it's better to sell off the backwater stocks like PHM in order to deploy more capital into the broader rally. As the rally continues, it will actually put downward pressure on names such as PHM, BTI, etc.